Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

Antonarakis et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69dd4e4d0644c7b49d40ccb0 — DOI: https://doi.org/10.1200/jco.19.01638

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology· 2018 · 1,615 citations
2. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)· 2008 · 29,261 citations
3. Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States· 2018 · 374 citations
4. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study· 2012 · 1,382 citations
5. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma· 2017 · 3,373 citations